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ABSTRACT
Recent studies suggest that head and neck squamous cell carcinomas are very 
heterogeneous between patients; however the subclonal structure remains unexplored 
mainly due to studies using only a single biopsy per patient. To deconvolute the 
clonal structure and describe the genomic cancer evolution, we applied whole-exome 
sequencing combined with ultra-deep targeted sequencing on oral squamous cell 
carcinomas (OSCC). From each patient, a set of biopsies was sampled from distinct 
geographical sites in primary tumor and lymph node metastasis.
We demonstrate that the included OSCCs show a high degree of inter-patient 
heterogeneity but a low degree of intra-tumor heterogeneity. However, some OSCC 
cancers contain complex subclonal architectures comprising distinct subclones only 
found in geographically distinct regions of the primary tumors. In several cases we 
find mutations in the primary tumor that are not present in the lymph node metastasis. 
We conclude that metastatic potential in our population is acquired early in tumor 
evolution as evident by the ongoing parallel evolution in several primary tumors.
INTRODUCTION
Head and neck cancer is the world’s 6th most 
common cancer form with more than a half million new 
cases a year. More than 90% of tumors are head and neck 
squamous cell carcinomas (HNSCC). Recent studies 
suggest that they are very heterogeneous between patients 
[1–11]. Oral squamous cell carcinoma (OSCC), a subgroup 
of HNSCC, is primarily attributed to alcohol consumption 
and tobacco use. The role of human papilloma virus 
(HPV) in OSCC is questionable. Recent international 
studies suggest that despite a higher HPV DNA prevalence 
than previously reported, HPV rarely plays a driving role 
in oncogenesis, because mRNA or p16 are detected in only 
3% to 5% of oral cavity cancers [12, 13]. 
OSCC is a loco-regional disease that mainly 
involves the oral cavity and cervical lymph nodes; distant 
metastasis is relatively rare in HNSCC compared to other 
cancer types. In a 2009 study, OSCC was shown to spread 
less frequently to distant sites compared to other HNSCC 
tumors localized at oropharynx, laryngopharynx and 
larynx, 6% vs 16% [14].
Intra-tumor heterogeneity and subclonal structure of 
OSCC (and HNSCC) have remained unexplored mainly 
due to studies using only a single biopsy per patient, as the 
use of a single tumor biopsy severely hinders the analysis 
of spatial intra-tumor heterogeneity. Analysis of intra-
tumor heterogeneity in HNSCC has previously been based 
on calculating a mutant-allele tumor heterogeneity score 
[15], which could be useful if only one biopsy is available. 
In order to avoid this limitation and to obtain a higher 
resolution, we sampled multiple tumor biopsies from 
each patient. Another limitation of the previous studies is 
the relatively low coverage obtained from whole-exome 
sequencing (WES). To deconvolute the clonal structure 
and describe the genomic cancer evolution, we applied 
WES combined with ultra-deep targeted sequencing on 
OSCCs with cervical lymph node involvement.
Research Paper
Oncotarget16572www.impactjournals.com/oncotarget
RESULTS
To evaluate the subclonal diversity of OSCC we 
analyzed three tumor biopsies (named front, center 
and back, respectively – Supplementary Figure 1) and 
one lymph node metastasis from 5 late stage patients 
(Supplementary Table 1) using whole-exome sequencing. 
Average coverage of WES across all samples was 95×. 
Possible somatic variants were selected and validated by 
targeted ultra-deep sequencing with an average coverage of 
1693× (Supplementary Table 2). Approximately 80% of the 
possible variants were confirmed. The number of mutations 
ranges from 27 to 156 in our population. Our data shows a 
significantly higher nonsynonymous to synonymous ratio 
that exceeds the 2:1 ratio [16] one would expect if these 
were random passenger mutations (p-value = 0.0002, 
Supplementary Table 9). The primary tumors were tested 
for p16 protein overexpression by immunohistochemistry 
which is used as a prognostic marker for HPV infection. 
Patient 5 was the only positive case. 
Intra-tumor heterogeneity
Heterogeneity analysis of the primary tumors 
demonstrates that biopsies from each patient typically share 
a common set of somatic mutations which comprises the 
majority of mutations found (Figure 1). Interestingly, in 
several cases we find mutations in the primary tumor that 
are not present in the lymph node metastasis. Lymph node 
metastasis specific mutations are observed in 2 of the 5 cases.
Genomic evolution and subclonal structure
In order to understand the subclonal evolution and 
progression of the cancers, we used copy number and 
mutational data to construct b-allele frequency vs copy 
number plots (Figure 2, Supplementary Figures 3–21). 
Based on these plots, we constructed a phylogenetic tree 
for each patient’s cancer (Figure 3) using the assumption 
that every clone inherits the ancestral clone’s somatic 
mutations, and each daughter subclone inherits their 
ancestor’s mutations. Analysis of the cancer in patient 1 
indicates 7 clones. The 2b-clone of patient 1 has given 
rise to three different daughter clones, and the cancers of 
patient 3 and 5 also exhibit numerous clones. New clones 
for patient 1 and 3 arise in the lymph node metastasis. 
In contrast, the cancers of patient 2 and 4 seem to be 
very homogenous as their biopsies share the same 
mutations with no evidence of intra-tumor heterogeneity. 
Additionally, we used the recently published tool 
BubbleTree [17] to run an independent heterogeneity 
analysis using copy number data from germline variants 
and somatic copy number aberrations obtained from 
the exome sequencing. The results verify our estimated 
tumor contents and the existence of the most prominent 
subclones we find, supporting our phylogenetic analysis.
Candidate cancer drivers
In the challenging process of identifying driver 
mutations, we analyzed recurrently mutated genes, 
bi-allelic alterations in the same gene, mutation type, 
iCAGES [18] candidate driver mutations, copy number 
and survival (Supplementary Tables 3–10, Supplementary 
Figure 2). Using this approach, we identified 21 genes as 
possible candidate cancer driver genes (Table 1), including 
7 top candidate genes: TP53, FAT1, DSEL, CALML5, 
DCLRE1C, MUC16 and KBTBD8. A few are already 
established as cancer related in the Catalogue Of Somatic 
Mutations In Cancer [19] or previous HNSCC studies, 
i.e. TP53, FAT1 [20] and MUC16, while the other 4 could 
possibly be novel drivers:
CALML5 not only gets mutated in patient 1 but 
also undergoes LOH, independently, in both the 3b- and 
3c-clones. DCLRE1C also undergoes two alterations in 
patient 1, firstly an early stopgain mutation in the1a-clone 
thereafter LOH in the 3b-clone in the nodal metastasis; 
both CALML5 and DCLRE1C are located on 10p. DSEL 
(synonym: C18orf4) and KBTBD8 both have a loss of 
function point mutation and undergo loss of the other allele. 
DISCUSSION
Ultra-deep targeted sequencing enabled us to obtain 
the subclonal structure with a previously unseen high 
resolution, and it enabled us to determine complex copy 
number events based on the clustering of point mutations 
(see for example Figure 2). Approximately 80% of the 
possible variants were confirmed. We chose to use very 
loose criteria for the selection of possible variants for 
validation, which explains why the number is not higher. 
This was done to minimize false negative variants, but 
by using loose criteria, a higher number of false positive 
variants are selected for validation. However, these false 
positive variants were consequently not validated because 
of the high coverage ultra-deep sequencing allows for. 
Our analysis of intra-tumor heterogeneity reveals a low 
number of prominent clones in each biopsy, from 1 to 3 
clones. This approach does not reject the possibility that 
minor subclones could exist at a very low frequency, as 
a reflection of the dynamic process of de novo mutations 
and selection. Our method for sampling multiple biopsies 
per primary tumor was chosen because it is easy and 
practical for the surgeon, it is consistent between different 
tumor sizes as we can change the size of the biopsy, and 
most importantly, it does not hinder the pathologist’s 
clinical analysis which is vital for determining the best 
possible treatment.
Analysis of the metastatic evolution revealed 
that in patient 1, 3 and 5 we observe additional specific 
primary tumor mutations that are not present in the lymph 
nodes, furthermore, none of the lymph nodes contain 
any mutations that are specific to a single primary tumor 
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Figure 2: B-Allele frequency (BAF) vs copy number plots for patient 1. LogR is defined as the Log2 copy number ratio between 
the tumor and matched normal sample. Each point represents a somatic point mutation and each circle represents a copy number event; 
each point and circle is color-coded according to the clonal structure of the phylogenetic tree (Figure 3). Overall, the bulk of mutations are 
clustered around a LogR of zero at half of the maximum BAF indicating the heterozygous positions (AB) of all cancer cells in the biopsy; 
no loss or gain events have occurred at AB. LOH (B) is seen at the lower right corner with a high BAF, indicating that both alleles have 
been altered, i.e. point mutation and loss of wildtype. AB: diploid, one mutation and one wildtype. BB: diploid, loss of wildtype and gain of 
mutation. ABB: triploid, gain of mutation without loss of wildtype. Tumor front: contains the 3a-clone which has inherited the mutations of 
the 2b- and 1a-clones. Tumor center: contains 2a, 2b and 3a. Tumor back: contains 2a and 3c; 3c has inherited the mutations of 2b. Orange/
blue highlighted LOH and BB seen for the mutations of 1a (BAF > 0.40) have occurred in one of the two clones. The highlighted orange/
blue B’s indicate subclonality, grey B circles indicate events present in all cells. It is important to note that BBs originate from their closest 
B. It is not possible to determine in which clone these copy events have occurred (2a or 3c), as both clones occur with the same frequency, 
so their mutations are clustered together. Lymph node: contains 3b and 4a. The mutations of 3b and 4a are biopsy specific.
Figure 1: Venn diagrams. Venn diagrams for all patients illustrating the shared mutations across biopsies. A mutation has to have 
sufficiently high enough alternative reads (B-alleles) before being counted (in this case, at least 5). It should be noted that tumor back in 
patient 5 was evaluated not to contain tumor tissue.
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location. This indicates that the metastatic potential is 
acquired early in the tumor evolution, because the primary 
tumor specific mutations were acquired after the cancer 
disseminated to the lymph node.  In 3 of 5 cases, we did 
not observe new mutations in the metastasis which could 
indicate that no new mutations are needed for survival 
and colonization. The latter is supported by a recent 
HNSCC study of nodal metastasis that shows a low 
degree of metastasis specific mutations [11]. However, 
low tumor content in patient 2, 4 and 5’s lymph node 
metastases lowers the resolution and ability to identify 
unique metastasis specific mutations by whole-exome 
sequencing in these patients. The tumor contents are high 
enough to confirm prominent mutations shared with their 
corresponding primary tumors due to the use of ultra-deep 
sequencing, but the detection of low frequency subclonal 
mutations is hampered even with our approach’s high 
coverage. To avoid this limitation in future studies, we 
recommend using a different sampling method to increase 
the tumor content in biopsies obtained from lymph node 
metastasis. We suggest that during the clinical assessment 
of lymph nodes the pathologist should determine tumor 
content, and take one or more samples from high tumor 
content areas for later sequencing. The lymph node biopsy 
should not be taken during surgery, as it can be hard to 
differentiate between cancerous and fibrous tissue.
Two types of mutations can exist in the lymph node, 
the first type of mutations originate from a clone in the 
primary tumor. These mutations are observed in all cancer 
cells in the lymph node. The second type of mutations are 
metastasis specific mutations only seen in the lymph node, 
either in all cancer cells or in a subclone. However, it is 
still possible that the unique mutations seen in all cancer 
cells, in the lymph node, could exist in their corresponding 
primary tumors, in a part we have not sampled or with a 
frequency below the detection limit.
Parallel evolution [21] is observed in the primary 
tumors of patient 1, 3 and 5; however, metastatic evolution 
is different in each case. For patient 1, parallel metastasis 
is observed as multiple new subclones arise in the primary 
tumor as well as in the node. Parallel metastasis is also 
seen in patient 3, as a new clone arises in the primary 
tumor and in the node. In patient 5 there are no signs 
of new clones in the metastasis. However, the primary 
tumor has evolved a new daughter clone originating 
from the same ancestral clone as the metastasis originates 
from.  No sign of polyclonal seeding is evident, as all the 
nodal metastases seem to be monoclonally seeded from 
their corresponding primary tumor. Our observations 
indicate that OSCC is different from other cancer types 
like breast cancer, where the metastases seem to originate 
from advanced subclones in the primary tumor [22], 
and prostate cancer where polyclonal seeding has been 
observed [23].
Examining the HPV p16 status of the primary 
tumors reveals that patient 5 is the only positive case; 
however, HPV infection does not seem to be the driving 
factor for carcinogenesis in this patient. HPV-negative 
tumors exhibit higher mutation rates than HPV-positive 
HNSCC tumors [1–3,10]. In this case, 116 mutations 
Figure 3: Phylogenetic trees for all patients. Each pie chart represents a biopsy; they indicate the distribution of clones in each 
biopsy as the ratio between BAF(ABsubclone) and BAF(ABall), please refer to Supplementary Note 1 for full details on construction of 
phylogenetic trees. Biopsy specific primary tumor mutations for patient 1 have been left out of the tree, since they either have a very low 
BAF or there are too few to base any conclusion on. Patient 5’s tumor back was left out, because it was evaluated not to contain any tumor 
by the pathologist, and the amount of mutations discovered are too few to base any conclusions on. There is no evidence of intra-tumor 
heterogeneity in patient 2 and 4. TF: Tumor front. TC: Tumor center. TB: Tumor back. LN: Lymph node.
Oncotarget16575www.impactjournals.com/oncotarget
were identified in patient 5 compared to the average of 
111 mutations in the remaining 4 HPV-negative cases. 
Additionally, the mutational profile of HPV-positive and 
HPV-negative are different with only a few overlapping 
gene mutations [10], while in contrast, we observe 11 
recurrent gene mutations in patient 5 compared to the 
average 8 in the HPV-negative tumors (Supplementary 
Table 10). TP53 is a common mutated gene in HPV-
negative HNSCC tumors in contrast to HPV-positive 
tumors [1–3, 8, 24], a gene also seen mutated in patient 5 
which further supports the notion that HPV infection does 
not seem be the driving factor for carcinogenesis. 
The higher nonsynonymous to synonymous ratio 
than the expected 2:1 reflects competitive advantage 
with positive selection of nonsynonymous mutations. 
This suggests a high number of cancer drivers in our 
population. Our approach to identify candidate cancer 
drivers revealed 4 possible novel candidate driver genes 
in OSCC: Firstly, CALML5 which encodes a skin-specific 
calcium-binding protein [25,26] that is involved in 
epidermal differentiation [27]. K63-linked ubiquitination 
of the CALML5-protein in premenopausal breast 
cancer patients is reported to be strongly implicated in 
carcinogenesis [26]. 
DCLRE1C which encodes the Artemis protein 
involved in DNA repair [28]. Cells with an Artemis protein 
deficiency are more sensitive to radiation [29], as they 
show a higher incidence of chromosome breaks following 
irradiation [30], which could be of therapeutic interest for 
tumors with loss-of-function DCLER1C mutations. 
DSEL (synonym: C18orf4) which encodes the 
dermatan sulfate epimerase-like protein that shows a 
significant homology with DSEP [31, 32] (synonym: 
SART-2), a squamous cell carcinoma antigen that can 
Table 1: Candidate cancer driver genes
Gene Recurrence iCAGES Loss-of-function LOH COSMIC (%) HR (95% CI)
TP53 X X X X 0.274 n.s.
FAT1 X X X 0.028 n.s.
DSEL X X X 0.010 n.s.
CALML5 X X* X** 0.002 1.39 (1.03−1.89)
DCLRE1C X X 0.004 1.40 (1.04−1.89)
MUC16 X X 0.077 1.82 (1.34−2.49)
KBTBD8 X X 0.005 1.41 (1.02−1.96)
APC X X 0.113 n.s.
BRCA1 X X 0.017 n.s.
CBL X X 0.016 n.s.
CHD7 X X 0.022 n.s.
CYP17A1 X X 0.004 n.s.
DST X X 0.016 n.s.
HSPA6 X X 0.005 n.s.
MYH14 X X 0.010 n.s.
NUPL1 X X 0.004 n.s.
PAFAH1B2 X X 0.000 n.s.
PHIP X X 0.011 n.s.
SPRY2 X X 0.002 n.s.
USP8 X X 0.007 n.s.
WDR45 X X 0.004 n.s.
To qualify as a candidate, the gene must at least fulfill 2 of the 4 criteria: Recurrence, iCAGES, Loss-of-function and LOH. 
The top 7 candidate genes have fulfilled 3 criteria and/or have a significant hazard ratio; these genes will be mentioned in the 
main text. Recurrence: is the gene recurrently mutated in our cohort. iCAGES: has the mutation been classified in iCAGES 
as a driver. Loss-of-function: is the mutation a frameshift indel, splice site or stopgain. LOH: has the gene undergone LOH. 
COSMIC: Percentage of gene mutated in the Catalogue of Somatic Mutations in Cancer. HR: Hazard ratio for loss of gene 
based on The Cancer Genome Atlas’s data from 522 HNSCC patients; p-value < 0.05 (Supplementary Figure 2). N.s.: not 
significant. X*: Missense mutation of CALML5 resulted in a significant ion charge change from negative to positive (glutamic 
acid to lysine). X**: LOH of CALML5 occurred independently in 2 distinct subclones. 
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induce HLA-24-restricted and tumor-specific cytotoxic 
T-lymphocytes [33]. Loss of DSEL may have weakened 
the immune system’s response to the cancer. 
Lastly, KBTBD8 which encodes a protein that 
recently was found co-localizing with α-tubulin on the 
spindle apparatus of mitotic cells suggesting a role in 
cell proliferation. However, further studies are needed 
to investigate this assumption [34]. The 4 identified 
novel candidate genes need to be investigated further 
in functional studies, before the certainty of their 
involvement in carcinogenesis and metastasis can be 
established.
Our results demonstrate that ultra-deep sequencing 
provides unseen high resolution enabling clear detection 
of subclonal structure. Primary treatment of OSCC is 
usually surgery but adjuvant radiotherapy can be applied 
[35]. Chemotherapy is used as a part of adjuvant treatment 
of late stage cancer, recurrence and metastasis [35], but not 
all patients can handle such a regime due to side effects 
and comorbidities. Future targeted medical treatments 
are needed to increase survival and reduce side effects, 
enabling more vulnerable patients to receive treatment. 
In cancer research, two clinical challenges regarding 
heterogeneity are currently being vigorously discussed: 
Is a single biopsy representative of the primary tumor’s 
mutational profile, and is a single biopsy taken from the 
primary tumor representative of metastasis. Our results 
indicate that OSCC is a cancer with many driver mutations, 
with a high degree of inter-patient heterogeneity but a low 
degree of intra-tumor heterogeneity. All biopsies from 
each patient share the majority of mutations and only a 
low number of prominent subclones exist. In several cases 
we find mutations in the primary tumor that are not present 
in the lymph node metastasis, which indicates that the 
metastatic potential, in our population, is acquired early in 
tumor evolution. It might just be a matter of time before 
metastasis occurs.
MATERIALS AND METHODS
Patient selection and sampling
Ethics approval was obtained from The Regional 
Scientific Ethical Committees for Southern Denmark and 
informed consent were acquired from the 5 patients that 
were included in this study. The study was carried out 
in accordance with the approved guidelines. All patients 
were characterized as having stage III or IV oral cavity 
carcinomas with cervical lymph node involvement. All 
patients were of Caucasian descent. Average age of the 
group was 56.2 years; 3 out of 5 had a history of smoking, 
and all patients had in various degrees consumed alcohol. 
Two patients were characterized as heavy drinkers. The 
tumors were tested for p16 overexpression which is used 
as a prognostic factor for HPV infection. None of the 
patients had distant metastasis, and no patient had received 
treatment for their condition prior to their operation. 
Patient characteristics are outlined in Supplementary 
Table 1. The operations took place at the Department of 
Plastic Surgery, Odense University Hospital, Denmark, 
which is the center for surgical treatment of oral cavity 
cancer for the Region of Southern Denmark’s 1.2 million 
inhabitants. From each patient, 5 samples were collected. 
One blood sample consisting of 10 mL of venous blood 
was drawn into a heparinized collection tube. Primary site 
tumor biopsies were taken from 3 different sites of the 
resected tumor: front, center and back. Lastly, 1 lymph 
node with signs of metastasis that was extracted during the 
neck dissection was collected. All samples were freshly 
frozen and stored at –80° Celsius for later use.
Pathology
The 20 tissue biopsies were evaluated by a 
pathologist to confirm the presence of squamous tumor 
cells. One biopsy, tumor back from patient 5, was 
evaluated not to contain any tumor tissue; the remaining 
primary tumor and lymph node biopsies contained 
between 20 to 80% tumor.  To minimize the presence 
of normal tissue in the lymph nodes, the pathologist 
marked the areas that contained tumor before being 
macroscopically dissected.
DNA extraction 
DNA from the 10 mL whole blood was extracted 
using the Gentra PureGene Blood kit (Qiagen) following 
the instructions provided by the manufacturer.  DNA was 
extracted from approximately 30 mg of primary tumor and 
lymph node biopsies using the AllPrep DNA/RNA Mini 
kit (Qiagen). 
Exome sequencing and validation
DNA extracted from the samples were subjected to 
sample preparation and exome capture by hybridization 
using TruSeq Exome Enrichment kit (Illumina) following 
the standard protocol provided by the manufacturer. 
Sequencing was carried out on the Illumina HiSeq1500 
platform with paired-end 2 × 100 base-pair reads. The 
filtered variants were validated by enriching the samples 
using Agilent SureSelect XT, and then sequenced on the 
same platform with a much higher coverage. Validation 
of variant positions was performed in all samples from 
all patients and not just in the samples where they were 
detected. Exome sequencing results of tumor center and 
back from patient 3 were not retrieved due to technical 
problems. However, both underwent validation, but it is 
only the mutations in tumor front and the lymph node that 
have been validated. No biopsy specific mutations have 
been validated in these biopsies.
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B-allele frequency
The B-allele frequency (BAF) represents the 
fraction of alternative reads (B-allele) in the tumor biopsy 
related to the sum of the reference reads (A-allele) and 
alternative reads. BAF is calculated as
allele reads
BAF
allele reads
 B
A B
=
−
+ −
BAF is calculated for somatic point mutations, but 
also for germline variants for use in copy number estimates.
Bioinformatics
Raw reads were aligned to the hg19 reference 
genome using Novoalign v. 3.01 (Novocraft) and 
processed according to Genome Analysis ToolKit Best 
Practice pipeline v. 2.7 (Broad Institute), including 
duplicate removal, indel realignment and base quality 
score recalibration [36, 37]. Calling of variants was 
performed using Varscan v. 2.3.4 [38], and Annovar 
(2013Aug23) [39] was used for annotation of variants. 
dbSNP build 138 [40] was used for filtering out known 
germline mutations. Only bases with a quality score of at 
least Q20 (corresponding to an error rate of 1:100) were 
considered. We used the following criteria to identify 
somatic mutations derived from the exome data: 
1. A variant should only be called if it had a BAF 
of at least 5% and had ≥ 3 alternative reads in one of the 
samples besides blood. 
2. To ensure that the B-allele was not a germline 
variant, the blood sample should at least have 10× 
coverage at the same position and have 0 alternative reads. 
The filtered variants were validated using ultra-deep 
sequencing. Before analyzing the validated data, we used 
the following criteria to ensure a reliable analysis: 
1. A variant should only be called if it had a BAF 
of at least 3% and had ≥ 10 alternative reads in one of the 
samples besides blood. 
2. To ensure that the B-allele was not a germline 
variant, the blood sample should at least have 50× 
coverage at the same position and have a BAF ≤ 1%. 
As stated, if a variant has a BAF of at least 3% and 
at least 10 alternative reads in one of the tissue biopsies, 
the variant will be called. This consequently means that 
we are more certain of the existence of the same variant 
in the other biopsies, even if BAF is under 3%; however, 
alternative reads should be sufficiently high enough to 
avoid false positive variants. 
BAF vs copy number plots
Copy number estimates were generated using 
ngCGH with a window size of 10,000 reads (https://
github.com/seandavi/ngCGH). LogR was defined as the 
Log2 copy number ratio between tumor and matched 
normal sample. Construction of the B-allele frequency 
vs copy number plots was performed by first finding the 
corresponding LogR value of each somatic mutation. This 
was done by creating a script in R which would search for 
each position in the raw copy number files obtained from 
ultra-deep sequencing. The values present in these files are 
representative for a range of positions; they are not values 
for each specific position. Essentially, the LogR value 
retrieved would be a mean estimate for the neighboring 
single nucleotide polymorphisms (SNPs), as the copy 
number values are based on SNPs and not on somatic 
mutations. For each patient, the values were plotted 
against each other, and the mutations were color coded 
during the analysis. Mutations were colored depending on 
how many biopsies they appeared in; if they appeared in 
all the biopsies they were not color coded (Supplementary 
Figures 3–21).
BubbleTree 
BubbleTree, a recently published method developed 
for aneuploidy and clonal visualization was used to run 
an independent heterogeneity analysis based on the BAF 
and LogR values of germline variants obtained from 
the exome sequencing. The copy number data were first 
segmented by the DNACopy package [41].
Phylogenetic trees
The phylogenetic trees are based on the BAF vs 
copy number plots (Supplementary Figures 3–21) and the 
mutational data (Supplementary Tables 3–7). Detecting 
possible subclones was done by visual interpretation 
of the plots (Supplementary Figure 22). Please refer to 
Supplementary Note 1 for full details. 
iCAGES
The iCAGES tool was used to identify driver 
mutations based on substitutional data. The tool includes 
3 layers of analysis. First layer integrates structural 
variations from coding, non-coding and to infer driver 
variants. The second layer identifies driver genes, by 
using information from the first layer and prior biological 
knowledge on gene-gene and gene-phenotype networks. 
Third layer prioritizes drug therapy based on the identified 
potential driver genes. However, iCAGES cannot, at this 
moment, identify driver mutations which are indels or 
splice site mutations. 
TCGA data retrieval
Data available on 522 HNSCC patients were 
retrieved from of The Cancer Genome Atlas (TCGA) 
Research Network (http://cancergenome.nih.gov). The 
dataset (TCGA_HNSC_gistic2thd) was extracted through 
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the UCSC Cancer Genomics Browser (https://genome-
cancer.ucsc.edu) on the 20th of October, 2015. TCGA’s 
datasets include curated survival data which we use for 
survival analysis.
Availability of data and material
The raw next-generation sequencing datasets 
generated during the current study are not publicly 
available due to it being against Danish legislation. 
However, interested parties will be able to obtain the data 
after consulting the Danish Data Protection Agency and 
The Regional Scientific Ethical Committees for Southern 
Denmark following a request to the corresponding author.
All other data analysed during this study are 
included in this published article and its Supplementary 
Information files.
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